Immune Support Peptides

A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.

A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.

A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.

A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.

A human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.

A thymic peptide preparation studied for immune system rejuvenation and age-related immune decline.

A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair.

A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure.

The first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics.

A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease.

A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market.